The human trials of the country’s first messenger mRNA vaccine is expected to begin in February amid a sharp rise in Covid-19 cases, official sources said on Monday. The Pune-based Gennova Biopharmaceuticals has submitted phase 2 data of mRNA vaccine and has also completed the recruitment of phase 3 data.
Drugs Controller General of India’s (DCGI) Subject Expert Committee (SEC) is expected to review the data soon, the official sources said. Gennova
Biopharmaceuticals has also developed the mRNA vaccine for the Omicron variant that will be tested on humans for efficacy and immunogenicity soon, the official sources said. Earlier in the month of September 2021, the Gennova issued a press statement and updated about the vaccine trials, “The Drug Controller General of India, had approved Phase II and Phase III study protocols for HGCO19, India’s first mRNA-based COVID-19 vaccine, developed by Gennova Biopharmaceuticals Limited (”Gennova”) back in August.”